info

Yes No
Global Header | Moody's
ABOUT US
REGULATORY AFFAIRS
CAREERS
Terms of Use
CONTACT US
HOME
Close
Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.
Close
Close
Please Log In to access this content

Registered User

Please log in for full access to your permissions. Password is case sensitive.
User Name:
Password:
Automatically log me in when I return
Forgot your Username or Password?
Or Log In using:

Not Registered Yet?

Register now to get FREE access to:

Issuer Ratings.

Ratings on over 170,000 corporate, government and structured finance securities.

Events Calendar.

Information about training seminars, briefings, and teleconferences.

Watchlists.

Listings of issuers under review for rating changes.

Rating Methodologies.

Descriptive frameworks underlying Moody's ratings.

 

Register Now
Beecham Group plc
Moody's Org ID:100100
Market Segment:Corporates
Industry:PHARMACEUTICALS: GENERAL & SPECIALTY
Peer Group:Pharmaceutical
Domicile:UNITED KINGDOM
Please Log In to view this content.
Research Ratings Family Tree Peer Group

Issuer Research Industry Research Family Tree Research Methodology
Results  1 - 50 Of  307
Previous  Page  Of  7  Next
Filter By:
Date Document Type Title Source
17 Apr 2019 Outlook
The document has been translated in other languages

Pharmaceuticals - Global: Product uptake drives stable outlook amid rising price pressure and regulatory threats
Moody's Investors Service
17 Apr 2019 Sector In-Depth
The document has been translated in other languages

Global Pharmaceuticals Snapshot: Patent cliff slightly eases while pipeline quality holds steady
Moody's Investors Service
10 Apr 2019 Compilation
The document has been translated in other languages

Inside Japan: April 2019
Moody's Investors Service
28 Feb 2019 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Europe: Capacity to absorb M&A without risking credit quality deterioration varies
Moody's Investors Service
18 Feb 2019 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Europe: Earnings growth set to accelerate, but move to specialty care raises business risks
Moody's Investors Service
07 Feb 2019 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - US: Increasing efforts to curb drug prices raise financial risk for pharmaceutical companies
Moody's Investors Service
18 Jan 2019 Sector Comment
The document has been translated in other languages

Pharmaceuticals - General & Specialty: Political risks, oncology market and acquisitions will shape industry in 2019
Moody's Investors Service
18 Jan 2019 Sector Comment
The document has been translated in other languages

Generic Pharmaceuticals - US : Developments to watch: 2019
Moody's Investors Service
18 Jan 2019 Compilation
The document has been translated in other languages

Healthcare Quarterly: January 2019
Moody's Investors Service
06 Dec 2018 Outlook
The document has been translated in other languages

Healthcare – Global: 2019 outlook reflects both rising spending and rising political risk (Slides)
Moody's Investors Service
27 Nov 2018 Outlook
The document has been translated in other languages

Non-financial corporates - Japan : 2019 Outlook (Slides)
Moody's Investors Service
15 Nov 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - US: Though down from their peak, cash levels are rising, portending more M&A ahead
Moody's Investors Service
31 Oct 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Global: Plan to lower Medicare Part B payments would pressure US drug prices, if adopted
Moody's Investors Service
22 Oct 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - US: Political risks rise as regulators contemplate ideas outlined in drug pricing blueprint
Moody's Investors Service
22 Oct 2018 Compilation
The document has been translated in other languages

Healthcare Quarterly: October 2018
Moody's Investors Service
18 Oct 2018 Sector In-Depth
The document has been translated in other languages

Non-financial companies - Japan: Cross-border financing rises as companies look abroad for growth
Moody's Investors Service
10 Oct 2018 Compilation
The document has been translated in other languages

Inside Japan: October 2018
Moody's Investors Service
10 Oct 2018 Sector In-Depth
The document has been translated in other languages

Non-financial companies - Japan: Cash level remains high, but growth will slow as spending increases
Moody's Investors Service
08 Oct 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Global : US approval of Hemlibra is credit positive for Roche, but will pressure rival drugs
Moody's Investors Service
04 Oct 2018 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - Global: Biosimilars: European sales accelerate, while regulatory changes will help US market
Moody's Investors Service
20 Sep 2018 Outlook
The document has been translated in other languages

Pharmaceuticals - Global: Modest pick-up in growth on strong product launches, but regulatory risk escalates
Moody's Investors Service
02 Aug 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Global: US drugs face heightened pricing pressure and regulatory risk
Moody's Investors Service
26 Jul 2018 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - Global: European Investor Roundtables - Q&A Highlights
Moody's Investors Service
12 Jul 2018 Sector Comment
The document has been translated in other languages

Generic Pharmaceuticals - US: Midyear update: Developments to watch in 2018
Moody's Investors Service
12 Jul 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - General & Specialty - US: Midyear update: M&A off to brisk pace globally, with more to come from US
Moody's Investors Service
12 Jul 2018 Compilation
The document has been translated in other languages

Healthcare Quarterly: July 2018
Moody's Investors Service
11 Jul 2018 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - Europe: Strong pipelines suggest acceleration of earnings growth into 2019
Moody's Investors Service
15 May 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Global: Proposals to lower US drug prices would be credit negative, if adopted
Moody's Investors Service
08 May 2018 Sector Comment
The document has been translated in other languages

Consumer, Tobacco and Pharmaceuticals: US: Companies invest in marijuana to learn more about its challenges and opportunities
Moody's Investors Service
20 Apr 2018 Sector In-Depth
The document has been translated in other languages

Global Pharmaceuticals Snapshot: Pipelines still good while patent expirations will remain modest over next three years
Moody's Investors Service
19 Apr 2018 Outlook
The document has been translated in other languages

Pharmaceuticals - Global: Stable outlook reflects modest earnings growth, but M&A event risk is rising
Moody's Investors Service
16 Apr 2018 Compilation
The document has been translated in other languages

Healthcare Quarterly: April 2018
Moody's Investors Service
16 Apr 2018 Sector Comment
The document has been translated in other languages

Branded Pharmaceuticals - US: Mergers of health plans and PBMs will target rising drug spending
Moody's Investors Service
10 Apr 2018 Compilation
The document has been translated in other languages

Inside Japan: April 2018
Moody's Investors Service
29 Mar 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Europe: Divestment of non-core assets will be a source of liquidity in 2018
Moody's Investors Service
12 Feb 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - Europe: M&A poses biggest downside risk to credit quality in 2018
Moody's Investors Service
23 Jan 2018 Sector In-Depth
The document has been translated in other languages

Generic pharmaceuticals - Europe: Market growth set to continue at a steady pace; more consolidation likely in 2018
Moody's Investors Service
10 Jan 2018 Sector Comment
The document has been translated in other languages

Pharmaceuticals - General & Specialty - US: Developments to watch: 2018
Moody's Investors Service
10 Jan 2018 Compilation
The document has been translated in other languages

Healthcare Quarterly: January 2018
Moody's Investors Service
09 Jan 2018 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - US: US tax reform will spur cash depletion, mainly for M&A and shareholder payouts
Moody's Investors Service
07 Dec 2017 Outlook
The document has been translated in other languages

Healthcare – Global: 2018 outlook reflects solid demographic trends and product innovation, offset by pricing pressure and political risk (Slides)
Moody's Investors Service
04 Dec 2017 Sector Comment
The document has been translated in other languages

Cross-Sector: CVS/Aetna cost-containment strategies would pressure other healthcare companies
Moody's Investors Service
30 Nov 2017 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals and Distributors - US: Drug manufacturers and distributors face rising risks related to the US opioid crisis
Moody's Investors Service
27 Nov 2017 Outlook
The document has been translated in other languages

Non-financial corporates - Japan: 2018 Outlook - Moderate global economic growth will support corporate earnings (Slides)
Moody's Investors Service
20 Nov 2017 Sector In-Depth
The document has been translated in other languages

Non-financial corporates - US: Corporate cash to rise 5% in 2017; top five cash holders remain tech companies
Moody's Investors Service
23 Oct 2017 Compilation
The document has been translated in other languages

Healthcare Quarterly: October 2017
Moody's Investors Service
23 Oct 2017 Sector Comment
The document has been translated in other languages

Pharmaceuticals - US : Pricing pressure, biosimilars and patent expirations will prompt cost reductions
Moody's Investors Service
19 Oct 2017 Compilation
The document has been translated in other languages

Inside Japan: October 2017
Moody's Investors Service
04 Oct 2017 Sector Comment
The document has been translated in other languages

Mylan N.V. and Teva Pharmaceutical Industries Ltd : Approvals of generic versions of Copaxone are credit positive for Mylan and negative for Teva
Moody's Investors Service
28 Sep 2017 Sector In-Depth
The document has been translated in other languages

Pharmaceuticals - Global : Biosimilars update: Market adoption faces hurdles but development continues apace
Moody's Investors Service
Results  1 - 50 Of  307
Previous  Page  Of  7  Next

6The rating history for this credit rating accurately reflects the current status of the (sf) indicator but, due to technical limitations, does not accurately reflect the (sf) indicator history. Please visit the Research tab to view the press release(s) announcing when the (sf) indicator was added or removed.

For credit ratings that are derived exclusively from an existing credit rating of a program, series, category/class of debt, support provider or primary rated entity, or that replace a previously assigned provisional rating at the same rating level, Moody’s publishes a rating announcement on that series, category/class of debt or program as a whole, on the support provider or primary rated entity, or on the provisional rating, but often does not publish a specific rating announcement on each subsequent bond or note for which the credit rating is derived from the existing credit rating. Rating announcements are usually press releases classified as Rating Actions on www.moodys.com. Please refer to the Research tab on the issuer/entity page for the rating announcement.
Global Footer | Moody's